A new study published in the prestigious journal Cell provides compelling evidence that autoantibodies may play a causal role in the neurological symptoms of Long COVID. CellTrend was also among the researchers. They found that some patients develop elevated levels of autoantibodies targeting structures of the central and peripheral nervous system. In animal models, these…
DetailsA new article will be published. In this study 96 Post-COVID patients, 59 ME/CFS patients and healthy controls were included. The results showed significantly higher ß2 adrenergic AAB titers than the other groups. Patients with post-COVID condition showed more pathological M3 muscarinic AAb results compared to the healthy control group. Read the article here.
DetailsThe international ME/CFS Symposium will take place again in Berlin on 7 and 8 May. CellTrend is a sponsor of this important event, where the current state of scientific research will be discussed and new project ideas will be developed. Online participation is free of charge upon registration (link below)! On Friday afternoon, the focus…
DetailsCellTrend was the first to describe autoantibodies against GLP-1R and has filed a patent application. This patent covers a test system for the diagnosis, prognosis, and treatment monitoring of myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) in patients. The anti-GLP-1R antibody can only be determined by CellTrend using serum analysis.
DetailsProf. Dr. Frank C. Mooren from Witten/Herdecke University School of Medicine, in collaboration with CellTrend, has shown that autonomic dysfunction in long COVID patients is induced by ATR1-Ab, ATR2-Ab, b1-adrenergic-R-Ab, b2-adrenergic-R-Ab, M1R-Ab, M3R-Ab, and CXCR3-Ab. For further information have a look here.
The aim of the “National Decade” is to research the causes and mechanisms of post-infectious diseases such as Long COVID or ME/CFS. The federal government has approved half a billion euros for this purpose from 2026 to 2036. According to Federal Research Minister Dorothe Bär, there is an enormous need for research into these diseases,…
DetailsIn the Tagesspiegel article from 17.05.25, Prof. Dr. Carmen Scheibenbogen spoke about the promising approach of an autoantibody study that was launched in 2023. This study investigated the question of whether autoantibodies trigger the symptoms of Long Covid and whether they can be removed with blood washing. The removal of these autoantibodies by means…
DetailsThe 3rd International ME/CFS Conference on May 12 and 13, 2025 in Berlin was a complete success. Organized by the Charité Fatigue Center (headed by Prof. Dr. Carmen Scheibenbogen), experts from all over the world gave lectures on aspects of pathogenesis, diagnostics and – most importantly – treatment options. The importance of the GPCR autoantibody…
DetailsThe serum samples of over 300 patients with primary Sjögren´s Syndrome (pSS) were investigate and compared with 50 healthy controls. CellTrend GmbH measured the IgG autoantibodies by ELISAs. The results showed significantly increased antibodies against M1, M2, M3, M4, M5 and CXCR3. The most abundant markers were anti-M2 and anti-CXCR3. Furthermore the presence of several…
DetailsThe Academy AONM is the new partner of CellTrend. For GPCR Autoantibody Testing from UK and Ireland, please have a look at this website. There you will find all necessary information.
Details
